Xue Lin

Summary of US Food and Drug Administration Chimeric Antigen Receptor T-Cell Biologics License Application Approvals From a Statistical Perspective.

Poornima Sharma, B. George, Shiowjen Lee, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma

Amy McKee, R. Pazdur, B. George, 2018, Clinical Cancer Research.

Creutzfeldt-Jakob Disease: Alterations of Gut Microbiota

Wenjie Sun, Qiang Shi, Xiao-Ping Dong, 2022, Frontiers in Neurology.

Effectiveness and tolerability of different therapies in preventive treatment of MOG-IgG-associated disorder: A network meta-analysis

Xiaofei Wang, Yanling Lang, Lingyao Kong, 2022, Frontiers in Immunology.

FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Ke Liu, Richard Pazdur, Xiaobin Lu, 2018, Clinical Cancer Research.

Graphical Analyses in the Regulatory Evaluation of Gene Therapy Applications

M. Lin, Shiowjen Lee, John Scott, 2020, Therapeutic Innovation & Regulatory Science.

FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.

Zhenzhen Xu, M. Theoret, D. Przepiorka, 2022, The oncologist.